Regeneron halts placebo enrollment in Covid-19 cocktail trial after IDMC finds 'clear' efficacy — but there are no data yet
Despite having already received an emergency use authorization for its Covid-19 antibody in non-hospitalized patients last November, Regeneron continued to conduct trials to evaluate the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.